Miscarriage · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate showed no clear difference in miscarriage rate per woman compared with clomiphene citrate alone (low certainty).
Live birth rate per woman aParticipants with BMI < 30 kg/m2 or ≤ 32 kg/m2 · women with polycystic ovary syndrome
It is very uncertain whether metformin changes live birth rate per woman aParticipants with BMI < 30 kg/m2 or ≤ 32… compared with clomiphene citrate (very low certainty).
Live birth rate per woman aParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome
It is very uncertain whether metformin changes live birth rate per woman aParticipants with BMI ≥ 30 kg/m2 compared with clomiphene citrate (very low certainty).
Gastrointestinal adverse events · women with polycystic ovary syndrome
The review found no eligible studies for this question.
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Clinical pregnancy rate per woman Participants with BMI < 30 kg/m2 or ≤ 32 kg/m2a · women with polycystic ovary syndrome
Metformin may leads to higher clinical pregnancy rate per womanaParticipants with BMI < 30 kg/m2… compared with clomiphene citrate (low certainty).
Clinical pregnancy rate per woman aParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome
Metformin may leads to lower clinical pregnancy rate per woman aParticipants with BMI ≥ 30 kg/m2 compared with clomiphene citrate (low certainty).
Ovulation rate per woman fParticipants with BMI < 30 kg/m2 · women with polycystic ovary syndrome
Metformin showed no clear difference in ovulation rate per woman fParticipants with BMI < 30 kg/m2 compared with clomiphene citrate (low certainty).
Ovulation rate per woman fParticipants with BMI ≥ 30 kg/m2 · women with polycystic ovary syndrome
Metformin may leads to lower ovulation rate per woman fParticipants with BMI ≥ 30 kg/m2 compared with clomiphene citrate (low certainty).
Live birth rate per woman · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate showed no clear difference in live birth rate per woman compared with clomiphene citrate alone (low certainty).
Gastrointestinal adverse events · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate probably leads to higher adverse events (gastrointestinal) per woman compared with clomiphene citrate alone (moderate certainty).
Clinical pregnancy rate · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate probably leads to higher clinical pregnancy rate per woman compared with clomiphene citrate alone (moderate certainty).
Ovulation rate · women with polycystic ovary syndrome
Metformin combined with clomiphene citrate may leads to higher ovulation rate per woman compared with clomiphene citrate alone (low certainty).
Side effects · Adults, 16 years and older (dentate)
Harms and adverse outcomes (SoF): Neither study reported any information about adverse events. Jared 2005 assessed adverse events (participants issued a symptom diary) but did not report the findings; Graziani 2017 did…
1 study
GRADE not reported
Not estimable. Only 1 study reported adverse outcomes in terms of problems with the use of the assigned interdental cleaning aids. (See comment) In this comparison the single study (Jared 2005) asked participants to…
1 study
GRADE not reported
Side effects · Adults, 16 years and older (dentate)
Five studies reported there were no adverse events. Two studies reported on problems with the use of interdental brushes or floss, which sometimes caused soreness. (Six studies reported on adverse events; none…
6 studies
GRADE not reported
Not estimable. 2 studies reported adverse outcomes in terms of problems with the use of the assigned interdental cleaning aids. We were unable to pool data. (See comment) Three further studies reported that no adverse…
5 studies
GRADE not reported
All‐cause mortality
Short‐acting insulin analogues showed no clear difference in all‐cause mortality (N) compared with regular human insulin (moderate certainty).
Severe hypoglycaemia
HbA1c (%)
Health‐related quality of life
All‐cause mortality · patients with type 2 diabetes mellitus
Intensive glycaemic control showed no clear difference in mortality compared with standard glycaemic control (moderate certainty).
Leaving the study early · patients with schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with placebo (very low certainty).